Compare VSTS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | HRMY |
|---|---|---|
| Founded | 1936 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 2.0B |
| IPO Year | N/A | 2020 |
| Metric | VSTS | HRMY |
|---|---|---|
| Price | $7.59 | $40.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.95 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 3.2M | 789.9K |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | ★ $2,734,839,000.00 | $825,944,000.00 |
| Revenue This Year | $1.47 | $23.11 |
| Revenue Next Year | $3.06 | $16.15 |
| P/E Ratio | ★ N/A | $12.79 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $3.98 | $25.52 |
| 52 Week High | $16.68 | $40.93 |
| Indicator | VSTS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 75.53 | 80.09 |
| Support Level | $7.10 | $38.12 |
| Resistance Level | $7.71 | $40.00 |
| Average True Range (ATR) | 0.40 | 1.20 |
| MACD | 0.09 | 0.25 |
| Stochastic Oscillator | 95.44 | 100.00 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.